title: [A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
abstract: OBJECTIVE
  To observe the efficacy and safety of bivalirudin use in Chinese patients with coronary heart disease (CHD) during the peri-percutaneous coronary intervention(PCI) period.
  
  
  METHODS
  A total of 3 271 patients who underwent PCI and received periprocedural bivalirudin treatment between July 2013 and October 2015 from 88 centers of China were involved in this study. The primary outcome was 30-day net adverse clinical events (NACE a composite of major adverse cardiac or cerebral events (MACE, all-cause death, reinfarction, urgent target vessel revascularization, or stroke) or bleeding), the secondary outcome was stent thrombosis at 30 days.
  
  
  RESULTS
  The mean age of enrolled patients was (65.12±12.44) years old, 27.4%(889/3 244) of them were female. Percent of stable coronary disease (SCD), non-ST segment elevation acute coronary syndrome (NSTE-ACS) and ST elevation myocardial infarction (STEMI) was 5.0%(162/3 248), 44.6%(1 450/3 248) and 50.4%(1 636/3 248) respectively. Radial access was performed in 89.5% (2 879/3 271) patients, and 9.7% (316/3 271) and 34.1% (1 115/3 271) patients also received ticagrelor and tirofiban medication. 69.3% (2 266/3 271) patients received post-procedural bivalirudin infusion, in which 46.3% (1 050/2 266) was treated at PCI-does, with a median duration of 2.5(1.0, 4.0) h. During the 30-day follow-up, NACE occurred in 3.45% (103/2 988) patients, the incidence of MACE, death was 2.17% (65/2 994) and 1.03% (31/3 017), respectively and bleeding events were recorded in 1.37% (41/2 996) patients. Four cases (0.13%) of stent thrombosis (3 acute stent thrombosis) were recorded.
  
  
  CONCLUSIONS
  Peri-PCI Bivalirudin use is safe and related with low bleeding risk in Chinese CHD patients.
authors.affiliation: Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110016, China.
authors.forename: Y L
authors.initials: YL
authors.lastname: Han
authors.forename: Y D
authors.initials: YD
authors.lastname: Chen
authors.forename: T M
authors.initials: TM
authors.lastname: Jiang
authors.forename: J B
authors.initials: JB
authors.lastname: Ge
authors.forename: X S
authors.initials: XS
authors.lastname: Cheng
authors.forename: J L
authors.initials: JL
authors.lastname: Li
authors.forename: Y G
authors.initials: YG
authors.lastname: Chen
authors.forename: Y T
authors.initials: YT
authors.lastname: Ma
authors.forename: Q
authors.initials: Q
authors.lastname: Xie
authors.forename: L K
authors.initials: LK
authors.lastname: Ma
authors.forename: X Q
authors.initials: XQ
authors.lastname: Zheng
authors.forename: B S
authors.initials: BS
authors.lastname: Yang
authors.forename: S L
authors.initials: SL
authors.lastname: Chen
authors.forename: G
authors.initials: G
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Zhao
authors.forename: H W
authors.initials: HW
authors.lastname: Liu
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Liang
authors.forename: M L
authors.initials: ML
authors.lastname: Liu
authors.forename: H Y
authors.initials: HY
authors.lastname: Wang
authors.forename: Y
authors.initials: Y
authors.lastname: Li
mesh_terms: D000368:Aged; D002681:China; D003327:Coronary Disease; D005260:Female; D006470:Hemorrhage; D006493:Heparin; D006629:Hirudins; D006801:Humans; D008297:Male; D010446:Peptide Fragments; D062645:Percutaneous Coronary Intervention; D011994:Recombinant Proteins; D012189:Retrospective Studies; D020521:Stroke; D000077466:Tirofiban; D014443:Tyrosine / Q000031:analogs & derivatives
chemical_list: D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban; C074619:bivalirudin